Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Marc Martino"'
Autor:
Thomas Perez, Jean-Robert Delpero, Michel Resbeut, Marc Martino, Gilles Houvenaeghel, Gérard Guerinel, Rolland Rosello, Jocelyne Jacquemier
Publikováno v:
Gynecologic Oncology. 55:393-400
From January 1988 to December 1992, 106 patients with advanced gynecologic cancer were preoperatively explored by clinical examination (CE) and endosonography (ESG) under anesthesia and by computed tomography (CT). Sixty-one tumors were primary and 4
Autor:
Gilles, Houvenaeghel, Marc, Martino, Max, Buttarelli, Vincent, Moutardier, Emmanuelle, Charaffe Jaufret, Isabelle, Rossi, Carole, Tarpin, Agnès, Tallet, Patrice, Viens, Jocelyne, Jacquemier
Publikováno v:
Bulletin du cancer. 91
Benefits provided by sentinel lymph node biopsy (SLNB) include improvement of pathologic examination and lower rate of sequels. The aim of this study was to assess the accuracy of this procedure in large tumors. From march 1999 and december 2003, 663
Autor:
J. Jacquemier, Marc Martino, Vincent Moutardier, A C Braud, Claire Julian-Reynier, A. Tallet, Sandrine Arnaud, I. Brenot-Rossi, M. Butarelli, Gilles Houvenaeghel
Publikováno v:
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 30(7)
Aims. The objectives of this study were to compare the postoperative morbidity of Sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) and to compare the views of surgeons and patients regarding postoperative morbidity. Methods
Autor:
Isabelle, Brenot-Rossi, Gilles, Houvenaeghel, Jocelyne, Jacquemier, Valérie-Jeanne, Bardou, Marc, Martino, Nathalie, Hassan-Sebbag, Jacques, Pasquier
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 44(8)
The aim of this study was to define the factors associated with nonvisualization of a sentinel node (SN) in the axilla area during preoperative lymphoscintigraphy.We retrospectively studied 332 women with T0, T1, or T23-cm, N0 invasive breast cancer